By Ryan Flinn Bloomberg News / June 17, 2012
Text size – +
Dendreon Corp., maker of the prostate cancer drug Provenge, rose the most in more than six months after Summer Street Research Partners recommended buying shares.
For more from BostonGlobe.com, sign up or log in below
To continue, please sign up or log in to BostonGlobe.com
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Are you a Boston Globe home delivery subscriber?
Get FREE access as part of your print subscription.
Click to continue reading this article or to log in to BostonGlobe.com.